24/7 Market News Snapshot 12 March, 2025 – Palisade Bio, Inc. Common Stock (NASDAQ:PALI)

March 12, 2025

DENVER, Colo., 12 March, 2025 (247marketnews.com) – (NASDAQ:PALI) are discussed in this article.
Palisade Bio, Inc. is currently witnessing a positive trend in its stock performance, with shares trading at $1.041 in the pre-market session, reflecting a notable 10.74% increase from the previous close of $0.940. Such growth is underpinned by robust trading activity, with a volume of 7.53 million shares exchanged, signaling strong investor interest and engagement. Analysts suggest this momentum may continue, recommending close monitoring of key resistance levels and technical indicators like moving averages to identify potential market entry or exit opportunities.

Adding to this positive outlook, Palisade Bio is proud to announce the selection of its innovative research for presentation at the esteemed Digestive Disease Week® (DDW) 2025, set to take place from May 3 to 6. The Company’s leading program, PALI-2108, a colon-specific PDE4 inhibitor prodrug aimed at treating ulcerative colitis, exemplifies its dedication to developing advanced therapies for autoimmune and inflammatory diseases.

During the conference, PALI-2108 data will be prominently featured in two significant poster presentations. The first, “A Bioinformatic Approach to PALI-2108 Treatment in Ulcerative Colitis Reveals the Potential for Anti-Fibrotic Efficacy with Local PDE4 Inhibition in Intestinal Fibrosis,” is scheduled for May 4, presenting compelling findings related to the drug’s impact. On May 5, the second poster will explore the pharmacological effects of PALI-2108, particularly its bioactivation in the colon, which leads to significant reductions in colon tissue PDE4B expression and enhanced cAMP levels, effectively curtailing TNF-α in a mouse model of colitis.

Participation in Digestive Disease Week® underscores Palisade Bio’s commitment to pioneering treatments that could greatly enhance patient outcomes in the realm of digestive diseases, positioning the Company as a leader addressing critical medical needs in this therapeutic area. As it advances through its clinical development pipeline, Palisade Bio remains focused on delivering innovative solutions for patients globally.

Related news for (PALI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.